BioSpace News Archive

Beactica Therapeutics AB, the Swedish precision oncology company, announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.

Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas.

Flagship Pioneering, the bioplatform innovation company, announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics.

Cambrex announced that Snapdragon Chemistry has completed the second phase of its 51,000 square foot expansion in Waltham, Massachusetts.

Coherus BioSciences, Inc. announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share.

The JAMP Pharma Group is pleased to announce the launch of PrJAMP Dapagliflozin, a generic alternative to the reference product Forxiga® d’Astrazeneca Canada Inc.

Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone) with a comparator, IV brexanolone.

Intrance Medical Systems, Inc. announced the appointment of Ashley Prange to the position of Vice President of Business Development.

Medical device company Linear Health Sciences announced it received an expanded indication from the U.S. Food & Drug Administration for its Orchid SRV™, a tension-activated breakaway safety release valve designed to reduce the risk of IV catheter failure and replacement in hospitals.

Dermavant Sciences today announced positive results from ADORING 1, the second of two double-blind, randomized, vehicle-controlled Phase 3 studies to evaluate the efficacy and safety of topical VTAMA® (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old with moderate to severe atopic dermatitis (AD).